- 7025 malaria professionals are enjoying the free benefits of MalariaWorld today

Who's online
There are currently 0 users and 205 guests online.
News Flash
Latest Jobs
Events 2010
Recent blog posts
- We thought we were down to 655.000 deaths in 2010, right?
- Job: Postdoctoral Fellow: Malaria resistance research
- Let the sun shine
- Postdoctoral Fellows: Malaria research
- Guest Editorial: Don't fake it!
- Loop mediated amplification question
- Criticism, Ideas and the Maya example
- Symposium: Malaria 2012: Drugs, Vaccines, and Pathogenesis
- OPEN ACCESS TO PUBLICLY FUNDED RESEARCH: PUBLISHERS ARE ACTING UP
- The last 'Last week at MalariaWorld' of 2011...a special message for you.
The performances of all four malaria RDT kits were acceptable, although Humasis Malaria P.f/Pan antigen test and CareStartTM Malaria Pf/Pv Combo test gave superior performances with ROK isolates.
Thrombospondin-related adhesive protein (TRAP) from Plasmodium vivax (P. vivax) became one of the important vaccine candidates for malaria, because P. vivax TRAP (PvTRAP) is responsible for the sporozoite–host interactions.
To develop a vivax malaria vaccine for blocking malarial transmission, the ookinete surface protein Pvs28 was cloned from Korean malaria patients using polymerase chain reaction.
These results suggest that sequence variations in the DHFR-TS represent the prevalence of antifolate-resistant P. vivax in Korea.
The Ookinete surface proteins of Plasmodium vivax (P. vivax), Pvs25 and Pvs28, were candidates for the transmission blocking vaccine (TBV), which exhibited great antigenic diversities among various isolates.